Amivantamab

Summary

Amivantamab (CHEMBL4297774) is an approved antibody (ATC L01FX18) targeting EGFR and MET; indicated across 7 conditions including non-small cell lung carcinoma and neoplasm; with CIViC clinical evidence for 5 variant-indication associations (e.g. EGFR Exon 20 Insertion in lung non-small cell carcinoma).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: L01FX18
• Targets: 2 (EGFR, MET)
• Indications: 7 conditions
• Clinical trials: 42
• Precision-oncology evidence (CIViC): 5 variant–indication associations

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297774
Name	Amivantamab
Type	Antibody
Max phase	4
ATC	L01FX18

Also known as: Amivantamab, Amivantamab vmjw, Amivantamab-vmjw, CNTO-4424, CNTO4424, JNJ 61186372, Jnj 61186372, JNJ-611, Jnj-61186372, JNJ-61186372, JNJ-6372, Rybrevant

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
EGFR	epidermal growth factor receptor	Binding	8.85	17.5%	P00533
MET	MET proto-oncogene, receptor tyrosine kinase	Binding	10.4	2.4%	P08581

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 2 target gene(s): EGFR, MET.

Top Reactome pathways

77 total, by targets touching each:

Pathway	Targets	Genes
PIP3 activates AKT signaling	2	EGFR, MET
Constitutive Signaling by Aberrant PI3K in Cancer	2	EGFR, MET
RAF/MAP kinase cascade	2	EGFR, MET
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	2	EGFR, MET
Signaling by ERBB2	1	EGFR
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	1	EGFR
Signaling by ERBB4	1	EGFR
SHC1 events in ERBB2 signaling	1	EGFR
PLCG1 events in ERBB2 signaling	1	EGFR
Developmental Biology	1	MET
Signal Transduction	1	MET
Disease	1	MET
Signaling by EGFR	1	EGFR
GRB2 events in EGFR signaling	1	EGFR
GAB1 signalosome	1	EGFR
SHC1 events in EGFR signaling	1	EGFR
EGFR downregulation	1	EGFR
GRB2 events in ERBB2 signaling	1	EGFR
PI3K events in ERBB2 signaling	1	EGFR
Negative regulation of the PI3K/AKT network	1	MET
Generic Transcription Pathway	1	MET
EGFR interacts with phospholipase C-gamma	1	EGFR
EGFR Transactivation by Gastrin	1	EGFR
PI3K/AKT Signaling in Cancer	1	MET
Semaphorin interactions	1	MET
Sema4D in semaphorin signaling	1	MET
Sema4D mediated inhibition of cell attachment and migration	1	MET
Axon guidance	1	MET
Signal transduction by L1	1	EGFR
Constitutive Signaling by EGFRvIII	1	EGFR

Dominant GO biological processes

GO term	Targets
signal transduction	2
cell surface receptor signaling pathway	2
neuron differentiation	2
positive regulation of transcription by RNA polymerase II	2
protein phosphorylation	2
cell surface receptor protein tyrosine kinase signaling pathway	2
cell morphogenesis	1
ossification	1
embryonic placenta development	1
positive regulation of protein phosphorylation	1
hair follicle development	1
ubiquitin-dependent protein catabolic process	1
epidermal growth factor receptor signaling pathway	1
salivary gland morphogenesis	1
learning or memory	1

Indications & clinical

Indications

7 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
non-small cell lung carcinoma	4	MONDO:0005233	EFO:0003060
neoplasm	4	MONDO:0005070	EFO:0000616
gastric neoplasm	2	MONDO:0021085	MONDO:0001056
salivary gland cancer	2	MONDO:0004669	MONDO:0004669
hepatocellular carcinoma	2	MONDO:0007256	EFO:0000182
head and neck squamous cell carcinoma	1	MONDO:0010150	EFO:0000181
lung neoplasm	1	MONDO:0021117	MONDO:0008903

Clinical trials

Total trials: 42.

Phase distribution

Phase	Trials
PHASE2	20
PHASE1/PHASE2	8
PHASE3	7
PHASE1	6
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04487080	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04538664	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
NCT04988295	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT05388669	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT06662786	PHASE3	RECRUITING	A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06750094	PHASE3	RECRUITING	A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT07276399	PHASE3	RECRUITING	A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT03767075	PHASE2	RECRUITING	A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
NCT05074940	PHASE2	ACTIVE_NOT_RECRUITING	Amivantamab in Adenoid Cystic Carcinoma
NCT05117931	PHASE2	ACTIVE_NOT_RECRUITING	A Study of Amivantamab in People With Esophagogastric Cancer
NCT05299125	PHASE2	ACTIVE_NOT_RECRUITING	Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations
NCT05379595	PHASE1/PHASE2	RECRUITING	A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
NCT05488314	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
NCT05498428	PHASE2	RECRUITING	A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
NCT05601973	PHASE2	ACTIVE_NOT_RECRUITING	Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI
NCT05663866	PHASE2	ACTIVE_NOT_RECRUITING	Premedication to Reduce Amivantamab Associated Infusion Related Reactions
NCT05801029	PHASE2	ACTIVE_NOT_RECRUITING	A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations
NCT05845450	PHASE2	RECRUITING	Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
NCT05845671	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations
NCT05908734	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
NCT06083857	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer
NCT06116682	PHASE2	RECRUITING	Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
NCT06385080	PHASE1/PHASE2	RECRUITING	A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
NCT06532032	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer
NCT06667076	PHASE2	RECRUITING	A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06784791	PHASE2	RECRUITING	Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)
NCT06855849	PHASE2	NOT_YET_RECRUITING	An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.
NCT07062354	PHASE2	ENROLLING_BY_INVITATION	Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer
NCT07227025	PHASE1/PHASE2	RECRUITING	A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
NCT07392658	PHASE2	RECRUITING	Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.
NCT07586202	PHASE2	NOT_YET_RECRUITING	A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
NCT04945733	PHASE2	TERMINATED	A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer
NCT04965090	PHASE2	COMPLETED	A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)
NCT05653427	PHASE2	TERMINATED	A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
NCT07042295	PHASE2	SUSPENDED	Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System
NCT02609776	PHASE1	ACTIVE_NOT_RECRUITING	Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
NCT04077463	PHASE1	ACTIVE_NOT_RECRUITING	A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
NCT06507306	PHASE1	RECRUITING	A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
NCT06632236	PHASE1	RECRUITING	5G-EMERALD: Amivantamab in Malignant Brain Tumours
NCT06816992	PHASE1	RECRUITING	ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

Clinical evidence (CIViC)

Variant × indication × effect (5 predictive associations from 5 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
EGFR Exon 20 Insertion	Lung Non-small Cell Carcinoma	Sensitivity/Response	Amivantamab	CIViC A	EID11227
EGFR Exon 20 Insertion	Lung Non-small Cell Carcinoma	Sensitivity/Response	Chemotherapy + Amivantamab	CIViC A	EID12014
EGFR L858R OR EGFR Exon 19 Deletion	Lung Non-small Cell Carcinoma	Sensitivity/Response	Lazertinib + Amivantamab	CIViC A	EID12131
EGFR L858R OR EGFR Exon 19 Deletion	Lung Non-small Cell Carcinoma	Sensitivity/Response	Carboplatin + Pemetrexed + Amivantamab	CIViC A	EID12156
EGFR Mutation	Lung Non-small Cell Carcinoma	Sensitivity/Response	Amivantamab + Lazertinib	CIViC B	EID12928

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

203 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
AFATINIB	ChEMBL + PubChem	Phase 4 (approved)	EGFR, MET
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	EGFR, MET
DACOMITINIB	ChEMBL + PubChem	Phase 4 (approved)	EGFR, MET
Pazopanib	ChEMBL + PubChem	Phase 4 (approved)	EGFR, MET
SELUMETINIB	ChEMBL + PubChem	Phase 4 (approved)	EGFR, MET
AFATINIB DIMALEATE	ChEMBL	Phase 4 (approved)	EGFR, MET
AXITINIB	ChEMBL	Phase 4 (approved)	EGFR, MET
BOSUTINIB	ChEMBL	Phase 4 (approved)	EGFR, MET
BRIGATINIB	ChEMBL	Phase 4 (approved)	EGFR, MET
CABOZANTINIB	ChEMBL	Phase 4 (approved)	EGFR, MET
CERITINIB	ChEMBL	Phase 4 (approved)	EGFR, MET
ERLOTINIB	ChEMBL	Phase 4 (approved)	EGFR, MET
FEDRATINIB	ChEMBL	Phase 4 (approved)	EGFR, MET
GEFITINIB	ChEMBL	Phase 4 (approved)	EGFR, MET
MIDOSTAURIN	ChEMBL	Phase 4 (approved)	EGFR, MET
NERATINIB	ChEMBL	Phase 4 (approved)	EGFR, MET
SORAFENIB	ChEMBL	Phase 4 (approved)	EGFR, MET
SUNITINIB	ChEMBL	Phase 4 (approved)	EGFR, MET
VANDETANIB	ChEMBL	Phase 4 (approved)	EGFR, MET
CANERTINIB	ChEMBL	Phase 3	EGFR, MET
CEDIRANIB	ChEMBL	Phase 3	EGFR, MET
LESTAURTINIB	ChEMBL	Phase 3	EGFR, MET
LINIFANIB	ChEMBL	Phase 3	EGFR, MET
POZIOTINIB	ChEMBL	Phase 3	EGFR, MET
QUERCETIN	ChEMBL	Phase 3	EGFR, MET
BEMCENTINIB	ChEMBL	Phase 2	EGFR, MET
BI-2536	ChEMBL	Phase 2	EGFR, MET
CENISERTIB	ChEMBL	Phase 2	EGFR, MET
CEP-32496	ChEMBL	Phase 2	EGFR, MET
DEFOSBARASERTIB	ChEMBL	Phase 2	EGFR, MET
ELLAGIC ACID	ChEMBL	Phase 2	EGFR, MET
FORETINIB	ChEMBL	Phase 2	EGFR, MET
ILORASERTIB	ChEMBL	Phase 2	EGFR, MET
OSI-632	ChEMBL	Phase 2	EGFR, MET
PELITINIB	ChEMBL	Phase 2	EGFR, MET
R-406	ChEMBL	Phase 2	EGFR, MET
SU-014813	ChEMBL	Phase 2	EGFR, MET
TOZASERTIB	ChEMBL	Phase 2	EGFR, MET
Binimetinib	PubChem	Approved	EGFR, MET
ABEMACICLIB	ChEMBL	Phase 4 (approved)	EGFR
ACALABRUTINIB	ChEMBL	Phase 4 (approved)	EGFR
ALECTINIB	ChEMBL	Phase 4 (approved)	EGFR
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	EGFR
BACITRACIN	ChEMBL	Phase 4 (approved)	EGFR
BITHIONOL	ChEMBL	Phase 4 (approved)	EGFR
CABOZANTINIB S-MALATE	ChEMBL	Phase 4 (approved)	MET
CAPMATINIB	ChEMBL	Phase 4 (approved)	MET
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	EGFR
CHROMIC CHLORIDE	ChEMBL	Phase 4 (approved)	EGFR
CISPLATIN	ChEMBL	Phase 4 (approved)	EGFR
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	EGFR
COLISTIN	ChEMBL	Phase 4 (approved)	EGFR
DABRAFENIB	ChEMBL	Phase 4 (approved)	MET
DASATINIB	ChEMBL	Phase 4 (approved)	EGFR
DOBUTAMINE	ChEMBL	Phase 4 (approved)	EGFR
DOCETAXEL	ChEMBL	Phase 4 (approved)	EGFR
EBASTINE	ChEMBL	Phase 4 (approved)	EGFR
ECONAZOLE	ChEMBL	Phase 4 (approved)	EGFR
ENSARTINIB	ChEMBL	Phase 4 (approved)	MET
ENTRECTINIB	ChEMBL	Phase 4 (approved)	MET